Paolo Borghetti

I am very happy and proud to present this work, the result of the collaboration of many highly qualified experts and the prestigious support of AIRO - Associazione Italiana di Radioterapia e Oncologia Clinica Lung Cancer lungcancerjournal.info/article/S0169-…

@DrRishabhOnco Thank you @DrRishabhOnco

🫁 Lung Cancer + Interstitial Lung Disease (ILD) 🌫️ 🎯 AIRO Delphi Consensus 2025 When fibrosis meets photons ⚡ 🇮🇹 Italian Association of Radiotherapy & Clinical Oncology (AIRO) brings expert guidance on how to safely deliver RT in this high-risk duo 👇 🧭 Key Recommendations 🔹 HRCT = Gold standard for ILD detection & risk stratification 🔹 MDT discussion mandatory before RT (Radiation Oncologist + Pulmonologist + Radiologist) 🔹 High-risk ILD (UIP/IPF) → ❌ RT may be contraindicated 🔹 Predictive dosimetry:  • MLD > 12 Gy or V20 > 25 % → ↑ Pneumonitis risk ☠️  • For SBRT → keep MLD < 4.5 Gy, V20 < 6.5 % ✅ 🔹 Antifibrotics (💊 Nintedanib / Pirfenidone) may reduce flares 🔹 Safer chemo partners: Cisplatin / Carboplatin + weekly (nab-)Paclitaxel or Vinorelbine  → 🚫 Avoid Gemcitabine / Docetaxel 🔹 Immunotherapy 💉 possible with close lung monitoring 🔹 Targeted therapy + RT ⚠️ pneumonitis risk - avoid overlap 🔹 Follow-up in ILD-experienced RT centers only 🏥 💬 Takeaway Radiotherapy isn’t forbidden - it’s a precision team effort 🧠🤝 ✅ Multidisciplinary planning ✅ Antifibrotic support ✅ Smart dose constraints 📖 Borghetti et al. Lung Cancer 2025. 🔗 doi.org/10.1016/j.lung… #OncoTwitter #LungCancer #RadiationOncology #ILD #MedTwitter @OncoAlert @esmo_open @ASTRO_org @ASCO @myESMO @ESMO_Open

4. Initial ctDNA data indicates potential for complete molecular response and encouraging long-term PFS

I am pleased to present the final results of the DUART phase 2 study on behalf of my co-authors and all investigators. Sponsored by AstraZeneca, the trial involved patients with unresectable stage 3 NSCLC who were ineligible for chemotherapy.

Key findings include: 1. Excellent safety and tolerability in an elderly, unfit population. 2. Median overall survival nearly doubled compared to existing radiotherapy. 3. Promising results from combining radiotherapy with palliative doses and immunotherapy.

Durvalumab after radiotherapy in patients with unresectable stage III non-small-cell lung cancer ineligible for chemotherapy: the DUART phase II nonrandomized controlled study☆ - ESMO Open esmoopen.com/article/S2059-…

Immunotherapy-based treatment versus Chemotherapy-only in Patients with Unresectable NSCLC with Disease Progression Post Chemoradiation and Durvalumab - European Journal of Cancer ejcancer.com/article/S0959-…

It's a pleasure to share this article! Thanks to @umbertoricardi and @ Sara Ramella doi.org/10.3389/fonc.2…

@finn_corinne @EORTC How is it possible for a survey to give shape to a consensus? This survey is a great work that shows the opinion of many specialists. Hasn't eortc also developed a Delphi consensus on the same topic?

📊 An International @EORTC Survey on Stage III NSCLC resectability: ✅ Resectable: Smaller tumors, w/ single-station N2 Larger tumours, w/ max N1 ❌ Unresectable: Bulky/invasive N2, N3 T4 tumours, w/ multi-station N2 Results shaped a consensual definition: lungcancerjournal.info/article/S0169-…

We need awareness today!!!!!

@AndrearicFili Belli loro…😂😂😂

With my colleague and friend Sara Ramella in San Diego for WCLC2024!

@DoctorJSpicer @jdoningtonmd Very interesting, but 31% of pts treated with neoadj chemo did adj RT. The main question in that study should be : RT before or after surgery… but unfortnately now it’s late for this question… (Congratulations for the debate to #elcc with @finn_corinne )

For those who claim that neoadj CRT is superior to neoadj chemo or chemo-IO, see below for @jdoningtonmd + our own work on this subject from a few years ago. Even when looking exclusively at high-volume institutions, there was no difference between chemo and CRT for DFS and OS in stage IIIA(N2): annalsthoracicsurgery.org/article/S0003-…

@AndrearicFili @IstTumori Congratulazioni e in bocca al lupo!!!

Starting tomorrow a new position as Head of Radiation Oncology at the world-class Cancer Center ⁦@IstTumori⁩ in Milan. So excited. It’s time to work for our patients and the future of cancer care, in the right place.

clinical-lung-cancer.com/article/S1525-… proud of these results and of the splendid collaboration with #airo lung study group and oligometastasis study group

@APassaroMD @ACaffulli CM816 did not include IIIB stage! 25% of IIIB stage in AEGAN trial makes it not completely comparable with CM816.

CM816, AEGAN & KN671 (ASCO23..) will be very similar when comparing EFS. pCR for AEGEN is 17.2% vs 24% in CM816….. Adding 1 year of IO, will improve OS? This is the question…with the clear answer of yes…but…probably not the most correct approach for all pts!

@brunomeduri @JCO_ASCO @OncoAlert Complimenti!!

5yr results of the phase 3 #IRMAtrial: EBRT #APBI b.i.d. associated with slightly increased rate of moderate soft tissue and bone toxicity and a slightly inferior cosmesis, though overall toxicity was in an acceptable range @JCO_ASCO #BCSM @OncoAlert ascopubs.org/doi/full/10.12…

@Valerio_Nardone @AiroLung @AIRO80327989 @ALESSIOBRUNI10 @stefanovagge @elisada84826918 @mat_sepu Congratulazioni!!

Congrats to Giuseppina De Marco and all the coAuthors for the Best Oral Presentation at #AIRO2022 @AiroLung @AIRO80327989 @ALESSIOBRUNI10 @stefanovagge @elisada84826918 @PaoloBorghetti2 @mat_sepu

l radioterapista svolge un ruolo fondamentale nel management del paziente malato di tumore, specialmente nel setting delle neoplasie polmonari stadio terzo non operabile. Affrontiamo il tema con @ALESSIOBRUNI10 nel nostro canale podcast 🎙️ #drtalk bit.ly/3SEeAeI

Il modo migliore per ammirare in remoto la "Notte stellata" di Van Gogh è fissare il centro della spirale per 20 secondi e poi guardare il dipinto